Sjögren’s syndrome and Sjögren’s disease are the same condition. The shift from “syndrome” to “disease” is an official name change, not a distinction between two separate diagnoses. If you’ve seen both terms and wondered whether they mean different things, the short answer is: they don’t. But the reasoning behind the change matters, and understanding it can reshape how you think about this condition.
Why the Name Changed
In medicine, a “syndrome” refers to a cluster of symptoms that tend to appear together, without a clear understanding of why. That label made sense decades ago when Sjögren’s was poorly understood. It no longer fits. Sjögren’s has specific autoimmune mechanisms, identifiable antibodies, and a well-characterized pattern of tissue destruction. Calling it a syndrome understates what it actually is.
An International Task Force on Nomenclature was established to address this. After reviewing the scientific literature and gathering input from both clinicians and patients worldwide, the group published the 2023 International Rome Consensus for the Nomenclature of Sjögren Disease (formally released in 2025). The consensus issued five recommendations, the central one being that “Sjögren disease” should replace “Sjögren syndrome” as the official term, with “SjD” as the standard abbreviation. The reasoning was straightforward: this is an independent systemic autoimmune disease with specific clinical features, blood markers, and understood pathology. “Syndrome” simply wasn’t accurate anymore.
For patients, the name change carries practical weight. Being told you have a “syndrome” can feel dismissive, as though your symptoms are vague or poorly defined. “Disease” signals that this is a recognized, serious medical condition with a biological basis, which can influence how insurers, employers, and even other doctors take it seriously.
What Sjögren’s Disease Actually Does
Sjögren’s disease is an autoimmune condition in which your immune system attacks the glands that produce moisture, particularly the salivary glands and tear glands. The hallmark symptoms are persistent dry eyes and dry mouth, but framing it as a “dryness disease” misses the bigger picture.
The underlying mechanism involves immune cells infiltrating these glands and directly damaging the tissue. B cells (a type of white blood cell) can trigger the death of gland cells through direct contact, not just through the antibodies they produce. Over time, this destruction reduces your body’s ability to produce saliva and tears, sometimes severely. But the immune attack doesn’t always stay confined to moisture-producing glands.
Beyond Dryness: Systemic Effects
Sjögren’s disease can affect organs and systems throughout the body. These broader effects, sometimes called extraglandular manifestations, are divided into two categories: non-visceral (joints, skin, muscles) and visceral (lungs, kidneys, nervous system, blood).
Lung involvement occurs in up to 20% of patients. Chronic dryness in the airways can cause a persistent dry cough, nasal crusting, hoarseness, and recurrent respiratory infections. Over time, this dryness may contribute to more serious complications like bronchiectasis (permanent widening of the airways) or interstitial lung disease, where scarring develops in the lung tissue.
Kidney problems are less common, reported in roughly 5% of patients, though likely underrecognized. The most typical form involves damage to the kidney’s filtering tubes, which can impair the body’s ability to regulate acid levels in the blood.
Neurological involvement can affect both the peripheral nerves (causing numbness, tingling, or pain in the hands and feet) and the central nervous system. Some patients also experience Raynaud’s phenomenon, where fingers or toes turn white or blue in response to cold or stress due to blood vessel spasms.
The most serious long-term risk is lymphoma. People with Sjögren’s disease face a 7 to 19 times higher risk of developing non-Hodgkin lymphoma compared to the general population. One specific type, which develops in the mucous membrane tissue of the salivary glands, carries a striking 1,000-fold increased risk. This is the highest lymphoma risk of any systemic autoimmune disease, which is another reason the “disease” label is more appropriate than “syndrome.”
Primary vs. Secondary: A Distinction That Still Matters
You may also encounter the terms “primary” and “secondary” Sjögren’s. These describe something different from the syndrome-to-disease name change. Primary Sjögren’s disease occurs on its own, as a standalone autoimmune condition. Secondary Sjögren’s occurs alongside another autoimmune disease, most commonly rheumatoid arthritis, lupus, or scleroderma.
The distinction matters for diagnosis and treatment. Primary Sjögren’s is diagnosed only after other conditions that can mimic it (such as active hepatitis C, sarcoidosis, or IgG4-related disease) have been ruled out. When Sjögren’s symptoms appear in someone who already has another connective tissue disease, it’s classified as secondary. The symptoms overlap significantly, but the treatment approach may differ because clinicians need to manage both conditions simultaneously.
How It’s Diagnosed
Diagnosis uses a weighted scoring system developed jointly by the American College of Rheumatology and the European Alliance of Associations for Rheumatology. A score of 4 or higher, drawn from five criteria, confirms the classification:
- Salivary gland biopsy showing clusters of immune cells (worth 3 points)
- Anti-SSA/Ro antibodies detected in blood (worth 3 points)
- Eye surface damage measured by special staining (worth 1 point)
- Tear production test showing 5 millimeters or less of moisture in 5 minutes (worth 1 point)
- Saliva flow rate of 0.1 milliliters per minute or less without stimulation (worth 1 point)
Either a positive biopsy or positive blood antibodies alone reaches the threshold of 3, meaning just one additional finding gets you to a diagnosis. In practice, many patients are diagnosed through a combination of the blood test and one or two of the dryness measures.
Despite these clear criteria, diagnosis is often delayed. On average, it takes about three years from the time symptoms first appear to receiving a formal diagnosis, according to Johns Hopkins Medicine. Part of this delay stems from the fact that dry eyes and dry mouth are common complaints with many possible causes, and many primary care providers don’t immediately think of an autoimmune condition.
Who Gets Sjögren’s Disease
Sjögren’s disease predominantly affects women, with rates roughly six times higher than in men. It can develop at any age but is most commonly diagnosed in middle adulthood. Global prevalence estimates vary widely depending on how studies define and detect the condition, but a pooled analysis across multiple countries found a prevalence of about 61 per 100,000 people. European-focused studies put the number somewhat lower, around 39 to 47 per 100,000.
These numbers almost certainly undercount actual cases, given the long diagnostic delay and the fact that many people with mild symptoms never seek evaluation from a rheumatologist. The true burden of the disease is likely higher than published estimates suggest.